Narrative synthesis of published literature
Research on Trazodone for PTSD-Related Sleep Disturbance
How trazodone fits into the broader, evolving picture of medication options for PTSD-related sleep problems, compared with more specifically studied alternatives like prazosin.
Published August 8, 2026. Reviewed by our editorial team on August 8, 2026.
Who was studied: Patients with PTSD experiencing sleep disturbance or nightmares, across published clinical literature
PTSD-related sleep disturbance, including nightmares, is a significant driver of impairment for many people with the condition, and various medications have been studied as potential aids alongside trauma-focused psychotherapy, which remains the primary evidence-based PTSD treatment. Trazodone is one such option that clinicians consider, largely based on its general sedative and sleep-architecture effects rather than PTSD-specific mechanism research.
Other medications, such as prazosin, have more PTSD-nightmare-specific research behind them, though results across the broader research literature on this topic have been described as mixed. This is an evolving area, and treatment decisions are generally individualized alongside a mental health provider experienced in trauma care.
Main result: Trazodone is described in clinical literature as one of several medication options used for PTSD-related sleep disturbance and nightmares, generally considered alongside — rather than as a clear first choice ahead of — options like prazosin, which has more PTSD-nightmare-specific study behind it.
Limitations: PTSD treatment research increasingly emphasizes trauma-focused psychotherapy as central, with medication (including trazodone) generally studied as an adjunct rather than a standalone primary treatment — so trazodone-specific PTSD data is more limited than data on integrated treatment approaches.
Not medical advice. This summary is educational and does not replace individualized guidance from your prescriber.
